Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd (SHA:688336)

China flag China · Delayed Price · Currency is CNY
59.38
-2.48 (-4.01%)
At close: Feb 27, 2026
133.78%
Market Cap 36.70B
Revenue (ttm) 4.20B
Net Income (ttm) 2.94B
Shares Out 618.09M
EPS (ttm) 4.76
PE Ratio 12.47
Forward PE 106.99
Dividend 0.12 (0.21%)
Ex-Dividend Date Nov 7, 2025
Volume 5,449,603
Average Volume 5,967,429
Open 61.61
Previous Close 61.86
Day's Range 59.13 - 61.61
52-Week Range 23.46 - 83.00
Beta 0.94
RSI 47.77
Earnings Date Mar 31, 2026

About SHA:688336

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of antibody drugs. Its products include YISAIPU, a tumor necrosis factor inhibitor type II-antibody fusion protein for the treatment of autoimmune rheumatism and immunology; Septin, an injection for anti-human epidermal growth factor receptor-2 treatment; and Jiannipa, a recombinant anti-CD25 humanized monoclonal antibody injection to prevent acute rejection caused by kidney transplantation. The company... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 1,023
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688336
Full Company Profile

Financial Performance

In 2024, SHA:688336's revenue was 1.19 billion, an increase of 17.70% compared to the previous year's 1.01 billion. Earnings were 704.58 million, an increase of 139.15%.

Financial Statements

News

There is no news available yet.